Hyperhomocysteinemia predicts renal function decline: A prospective study in hypertensive adults

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Xie, Di ^a   Yuan, Yan ^a   Guo, Jiangnan ^a   Yang, Shenglin ^a   Xu, Xin ^a   Wang, Qin ^a   Li, Youbao ^a   Qin, Xianhui ^a   Tang, Genfu ^b   Huo, Yong ^c   Deng, Guangpu ^a   Wu, Shengjie ^a   Wang, Binyan ^a,b   Zhang, Qin ^a   Wang, Xiaobin ^d   Fang, Pu ^e   Wang, Hong ^e   Xu, Xiping ^a   Hou, Fanfan ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

AGED; BLOOD; BLOOD PRESSURE; COHORT ANALYSIS; COMPLICATION; DEMOGRAPHY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR;

AGED; BLOOD PRESSURE; COHORT STUDIES; DEMOGRAPHY; FEMALE; FOLIC ACID; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; VITAMIN B 12;

EID: 84947288762     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16268     Document Type: Article

References (45)

1. Coresh, J., et al. Prevalence of chronic kidney disease in the United States. JAMA 298, 2038-2047 (2007).
2. Zhang, Q. L. & Rothenbacher, D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 8, 117 (2008).
3. Zhang, L., et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 379, 815-822 (2012).
4. Hsu, C. Y., McCulloch, C. E., Darbinian, J., Go, A. S. & Iribarren, C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 165, 923-928 (2005).
5. Tozawa, M., et al. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 41, 1341-1345 (2003).
6. Klag, M. J., et al. Blood pressure and end-stage renal disease in men. N Engl J Med 334, 13-18 (1996).
7. Ninomiya, T., et al. Hyperhomocysteinemia and the development of chronic kidney disease in a general population: the Hisayama study. Am J Kidney Dis 44, 437-445 (2004).
8. Fox, C. S., et al. A multi-marker approach to predict incident CKD and microalbuminuria. J Am Soc Nephrol 21, 2143-2149 (2010).
9. Shastry, S., Ingram, A. J., Scholey, J. W. & James, L. R. Homocysteine induces mesangial cell apoptosis via activation of p38- mitogen-activated protein kinase. Kidney Int 71, 304-311 (2007).
10. Yi, F., et al. Inhibition of ceramide-redox signaling pathway blocks glomerular injury in hyperhomocysteinemic rats. Kidney Int 70, 88-96 (2006).
11. Sethi, A. S., Lees, D. M., Douthwaite, J. A., Dawnay, A. B. & Corder, R. Homocysteine-induced endothelin-1 release is dependent on hyperglycaemia and reactive oxygen species production in bovine aortic endothelial cells. J Vasc Res 43, 175-183 (2006).
12. Yi, F. & Li, P. L. Mechanisms of homocysteine-induced glomerular injury and sclerosis. Am J Nephrol 28, 254-264 (2008).
13. Lee, M. E. & Wang, H. Homocysteine and hypomethylation. A novel link to vascular disease. Trends Cardiovasc Med 9, 49-54 (1999).
14. Marti, F., et al. Hyperhomocysteinemia is independently associated with albuminuria in the population-based CoLaus study. BMC Public Health 11, 733 (2011).
15. Jager, A., et al. Serum homocysteine levels are associated with the development of (micro)albuminuria: the Hoorn study. Arterioscler Thromb Vasc Biol 21, 74-81 (2001).
16. Chen, N. C., et al. Regulation of homocysteine metabolism and methylation in human and mouse tissues. FASEB J 24, 2804-2817 (2010).
17. Frosst, P., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10, 111-113 (1995).
18. Stampfer, M. J. & Malinow, M. R. Can lowering homocysteine levels reduce cardiovascular risk? N Engl J Med 332, 328-329 (1995).
19. Rimm, E. B., et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 279, 359-364 (1998).
20. Gao, Y., et al. Prevalence of hypertension in china: a cross-sectional study. PLoS One 8, e65938 (2013).
21. Hao, L., et al. High prevalence of hyperhomocysteinemia in Chinese adults is associated with low folate, vitamin B-12, and vitamin B-6 status. J Nutr 137, 407-413 (2007).
22. Hao, L., et al. Geographical, seasonal and gender differences in folate status among Chinese adults. J Nutr 133, 3630-3635 (2003).
23. Botto, L. D. & Yang, Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 151, 862-877 (2000).
24. Huo, Y., et al. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA 313, 1325-1335 (2015).
25. Veeranna, V., et al. Homocysteine and reclassification of cardiovascular disease risk. J Am Coll Cardiol 58, 1025-1033 (2011).
26. Kang, S. S., Wong, P. W. & Malinow, M. R. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 12, 279-298 (1992).
27. Stanger, O., et al. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases. Z Kardiol 93, 439-453 (2004).
28. Towfighi, A., Markovic, D. & Ovbiagele, B. Pronounced association of elevated serum homocysteine with stroke in subgroups of individuals: a nationwide study. J Neurol Sci 298, 153-157 (2010).
29. Bostom, A. G., et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 131, 352-355 (1999).
30. Boushey, C. J., Beresford, S. A., Omenn, G. S. & Motulsky, A. G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274, 1049-1057 (1995).
31. Malinow, M. R., Nieto, F. J., Szklo, M., Chambless, L. E. & Bond, G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. Circulation 87, 1107-1113 (1993).
32. Nygard, O., et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337, 230-236 (1997).
33. Wilcken, D. E. & Wilcken, B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis 20, 295-300 (1997).
34. den Heijer, M., Rosendaal, F. R., Blom, H. J., Gerrits, W. B. & Bos, G. M. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 80, 874-877 (1998).
35. Wald, D. S., Law, M. & Morris, J. K. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 325, 1202 (2002).
36. Wang, X., et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369, 1876-1882 (2007).
37. Jiang, X., et al. Hyperhomocystinemia impairs endothelial function and eNOS activity via PKC activation. Arterioscler Thromb Vasc Biol 25, 2515-2521 (2005).
38. Jamaluddin, M. D., et al. Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. Blood 110, 3648-3655 (2007).
39. Cheng, Z., Yang, X. & Wang, H. Hyperhomocysteinemia and Endothelial Dysfunction. Curr Hypertens Rev 5, 158-165 (2009).
40. Qin, X., et al. Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: a meta-analysis of randomized controlled trials. Clin Nutr 32, 722-727 (2013).
41. Levey, A. S., et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53, 766-772 (2007).
42. Junge, W., Wilke, B., Halabi, A. & Klein, G. Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffe method. Clin Chim Acta 344, 137-148 (2004).
43. Levey, A. S., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150, 604-612 (2009).
44. Madero, M., et al. Association of arterial rigidity with incident kidney disease and kidney function decline: the Health ABC study. Clin J Am Soc Nephrol 8, 424-433 (2013).
45. Ford, E. S. & Bowman, B. A. Serum and red blood cell folate concentrations, race, and education: findings from the third National Health and Nutrition Examination Survey. Am J Clin Nutr 69, 476-481 (1999).